Omega-3 EPA and DHA Supplementation Reduces Risk of Cardiac Death in New Meta-Analysis


The meta-analysis, comprising 14 randomized, controlled trials featuring 71,899 subjects, found that omega-3s EPA and DHA supplementation may reduce the risk of cardiac death by 8%, and that benefits may be even greater for subjects with elevated triglycerides or LDL cholesterol.

Photo ©

A new meta-analysis published in the Journal of Clinical Lipidology1 has concluded that EPA and DHA omega-3 fatty acid supplementation helps reduce the risk of coronary mortality, also known as “cardiac death.” The study, which was funded by the Global Organization for EPA and DHA Omega-3s (GOED; Salt Lake City, UT), is the “first published meta-analysis to include cardiac death…as a primary endpoint, and the most comprehensive review of the evidence to date,” the association says. The meta-analysis, comprising results from 14 randomized, controlled trials featuring 71,899 subjects, found that omega-3 supplementation (either via dietary supplements or pharmaceuticals) may reduce the risk of cardiac death by 8%. In addition, the meta-analysis indicated an even greater risk reduction of 17% in subjects with already elevated triglycerides or LDL cholesterol.

GOED notes that cardiac death currently accounts for roughly two-thirds, or 405,000, of all cardiovascular disease deaths in the United States annually. Globally, cardiac death accounts for 42% of cardiovascular disease deaths annually, or 7.4 million people.

All of the studies included in the meta-analysis were conducted over a period of at least six months and with the specific endpoint of investigating the effects of omega-3 supplementation on cardiac death. Researchers analyzed data from studies that were published through December 2016 that included both dietary supplement and pharmaceutical omega-3 interventions. (The meta-analysis did not include studies examining the effects of dietary EPA and DHA consumed from fish.)

Overall, the researchers found that supplemental EPA and DHA omega-3s reduced the risk of cardiac death by a statistically significant average of 8%. The study authors found that, in the omega-3 groups, there were 1,613 cardiac deaths recorded (4.48% of subjects), while in the control groups 1,746 cardiac deaths were recorded (4.87% of subjects).

Meanwhile, the researchers found greater risk reduction in subjects with high triglycerides and LDL cholesterol, findings that are in line with the theory that omega-3 supplementation may be most beneficial for reducing cardiac death in higher-risk individuals. This is a significant hypothesis because, as GOED notes, the National Center for Health Statistics estimates that 25% of adults in the United States have high triglyceride levels (≥150 mg/dL) and that 27% have LDL cholesterol levels greater than or equal to 130 mg/dL.

The researchers also found the greatest reduction in cardiac death rates-an almost 30% risk reduction-in those trials that utilized omega-3 dosages of more than 1 g of EPA and DHA per day.

These results counter suggestions that omega-3s don’t benefit cardiovascular disease risk reduction. Harry B. Rice, PhD, vice president of regulatory and scientific affairs, GOED, stated in a press release: “This study is important because it explored the effects of omega-3s on a specific outcome of coronary heart disease. A number of studies in recent years have questioned omega-3 benefits in cardiovascular diseases. In order to understand the role omega-3s play in the cardiovascular system, however, research has to focus on a specific disease rather than all cardiovascular outcomes together. This is an important nuance that this meta-analysis helps clarify.”

Kevin Maki, PhD, lead study author and chief scientist for Midwest Biomedical Research’s Center for Metabolic and Cardiovascular Health, added: “It’s important to note that these results align with the conclusions in the recent Science Advisory from the American Heart Association, which states that EPA and DHA omega-3 treatment ‘is reasonable’ for secondary prevention of coronary heart disease and sudden cardiac death. One notable feature of EPA and DHA omega-3 supplementation is the low risk associated with its use. Because of the low risk for adverse effects, even a modest benefit is clinically meaningful.”



Also read: 

Omega-3 Discoveries: New Lipids, New Benefits

Asian Omega-3 Market Poised for Double-Digit Growth through 2017, GOED Reports

Adults Should Consume 500 mg EPA and DHA Omega-3s Daily, GOED Says


  1. Maki KC et al., “Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps.” Journal of Clinical Lipidology. Published online August 2, 2017. 
Related Videos
Nils Hoem and Nutritional Outlook editor Sebastian Krawiec
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.